Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity

(2015) Linda S. Steelman et al.   Oncotarget

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

Putting the brakes on p53-driven apoptosis

(2012) Katja Höpker et al.   CELL CYCLE

The evolution of the p53 family of genes

(2012) Arnold J. Levine   CELL CYCLE

 p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors

(2012) Mourad Sanhaji et al.   CELL CYCLE

p53 reactivation

(2012) Gabriella D’Orazi et al.   CELL CYCLE

Directing p53 to induce autophagy

(2012) Lindsey D. Mayo   CELL CYCLE

Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB

(2012) Carolina Vicente-Dueñas et al.   CELL CYCLE

p53-Aurora A mitotic feedback loop regulates cell cycle progression and genomic stability

(2012) Cheng-Ming Chiang   CELL CYCLE

DEC1 and MIC-1

(2012) Yingjuan Qian et al.   CELL CYCLE

A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer

(2012) Peter M. Ellis et al.   Clinical Lung Cancer

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

(2012) A. Frost et al.   Current Oncology

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study

(2012) Julie M. Vose et al.   LEUKEMIA & LYMPHOMA

Polo-Box Domain Inhibitor Poloxin Activates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in Vivo

(2011) Juping Yuan et al.   AMERICAN JOURNAL OF PATHOLOGY

Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21WAF1/CIP1

(2011) Nina-Naomi Kreis et al.   CELL CYCLE

Biological impact of freezing Plk1 in its inactive conformation in cancer cells

(2011) Sarah Keppner et al.   CELL CYCLE

Three independent mechanisms for arrest in G2after ionizing radiation

(2011) Kirsti Solberg Landsverk et al.   CELL CYCLE

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Chromosome Segregation Errors as a Cause of DNA Damage and Structural Chromosome Aberrations

(2011) A. Janssen et al.   SCIENCE

p53-dependent repression of polo-like kinase-1 (PLK1)

(2010) Lynsey McKenzie et al.   CELL CYCLE

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Functional and Spatial Regulation of Mitotic Centromere- Associated Kinesin by Cyclin-Dependent Kinase 1

(2010) Mourad Sanhaji et al.   MOLECULAR AND CELLULAR BIOLOGY

Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability

(2010) Y. Degenhardt et al.   MOLECULAR CANCER THERAPEUTICS

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells

(2010) N N Kreis et al.   ONCOGENE

The Plk1 Inhibitor BI 2536 Temporarily Arrests Primary Cardiac Fibroblasts in Mitosis and Generates Aneuploidy In Vitro

(2010) Bo Lu et al.   PLoS One

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis

(2009) Wolfgang Reindl et al.   CHEMBIOCHEM

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Plk1-mediated Phosphorylation of Topors Regulates p53 Stability

(2009) Xiaoming Yang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Polo-like kinases: conservation and divergence in their functions and regulation

(2009) Vincent Archambault et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions

(2008) Wolfgang Reindl et al.   CHEMISTRY & BIOLOGY

Polo and Aurora kinases—lessons derived from chemical biology

(2008) Stephen Taylor et al.   CURRENT OPINION IN CELL BIOLOGY

Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1

(2008) Mark Petronczki et al.   DEVELOPMENTAL CELL

Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition

(2008) Nobumoto Watanabe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY